Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care

NCT04864847 is registered in ClinicalTrials.gov with Hikari Dx, Inc. as lead sponsor.

NCT NCT04864847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04864847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care
Lead sponsor
Hikari Dx, Inc.
Phase
Observational
Overall status
Completed
Start date
October 1, 2021
Completion date
February 5, 2026
Enrollment
382 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, contrast-induced nephropathy